Drug Profile
Lifirafenib - BeiGene
Alternative Names: BeiGene 283; BGB 283; BGB-283-sesqui-maleate; Lifirafenib maleateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BeiGene
- Developer BeiGene; SpringWorks Therapeutics
- Class Antineoplastics; Benzimidazoles; Benzofurans; Cyclopropanes; Naphthyridines; Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 17 Apr 2023 Efficacy and adverse events data from a phase-Ib trial in Solid tumour released by BeiGene